115 related articles for article (PubMed ID: 16680561)
21. Effect of venlafaxine on imipramine metabolism.
Albers LJ; Reist C; Vu RL; Fujimoto K; Ozdemir V; Helmeste D; Poland R; Tang SW
Psychiatry Res; 2000 Nov; 96(3):235-43. PubMed ID: 11084219
[TBL] [Abstract][Full Text] [Related]
22. The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Nguyen HQ; Callegari E; Obach RS
Drug Metab Dispos; 2016 Oct; 44(10):1569-78. PubMed ID: 27440861
[TBL] [Abstract][Full Text] [Related]
23. Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin.
Padhi D; Sullivan JT
Drugs R D; 2007; 8(2):79-87. PubMed ID: 17324005
[TBL] [Abstract][Full Text] [Related]
24. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ
Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
[TBL] [Abstract][Full Text] [Related]
25. The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Kurtz DL; Bergstrom RF; Goldberg MJ; Cerimele BJ
Clin Pharmacol Ther; 1997 Aug; 62(2):145-56. PubMed ID: 9284850
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Hynes SM; Wickremsinhe E; Zhang W; Decker R; Ott J; Chandler J; Mitchell M
Biopharm Drug Dispos; 2015 Jan; 36(1):49-63. PubMed ID: 25296725
[TBL] [Abstract][Full Text] [Related]
27. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine.
Shimoda K; Morita S; Hirokane G; Yokono A; Someya T; Takahashi S
Pharmacol Toxicol; 2000 Jun; 86(6):245-9. PubMed ID: 10895986
[TBL] [Abstract][Full Text] [Related]
28. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
29. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial.
Murphy MP; Beaman ME; Clark LS; Cayouette M; Benson L; Morris DM; Polli JW
Pharmacogenetics; 2000 Oct; 10(7):583-90. PubMed ID: 11037800
[TBL] [Abstract][Full Text] [Related]
30. Managing rapid metabolizers of antidepressants.
Kraus RP; Diaz P; McEachran A
Depress Anxiety; 1996-1997; 4(6):320-7. PubMed ID: 9166660
[TBL] [Abstract][Full Text] [Related]
31. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
[TBL] [Abstract][Full Text] [Related]
32. Phenobarbital induces the 2-hydroxylation of desipramine.
Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
Ther Drug Monit; 1996 Feb; 18(1):60-4. PubMed ID: 8848823
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
34. Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.
Gueorguieva I; Jackson K; Wrighton SA; Sinha VP; Chien JY
Br J Clin Pharmacol; 2010 Oct; 70(4):523-36. PubMed ID: 20840444
[TBL] [Abstract][Full Text] [Related]
35. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers.
Bello CL; LaBadie RR; Ni G; Boutros T; McCormick C; Ndongo MN
Cancer Chemother Pharmacol; 2012 Apr; 69(4):991-7. PubMed ID: 22147075
[TBL] [Abstract][Full Text] [Related]
36. Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice.
Shen HW; Yu AM
Drug Metab Lett; 2009 Dec; 3(4):234-41. PubMed ID: 19995332
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.
Harris RZ; Padhi D; Marbury TC; Noveck RJ; Salfi M; Sullivan JT
Am J Kidney Dis; 2004 Dec; 44(6):1070-6. PubMed ID: 15558528
[TBL] [Abstract][Full Text] [Related]
38. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
[TBL] [Abstract][Full Text] [Related]
39. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]